文献速递关节外科

阿司匹林与口服Xa因子抑制剂在全膝关节置换术后血栓预防中的经济负担比较

The Financial Burden of Aspirin versus Oral Factor Xa Inhibitors for Thromboprophylaxis Following Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2023-10-18

该研究基于单一大型机构已发表的原发性全膝关节置换术后阿司匹林与Xa因子抑制剂血栓预防的假体周围感染率,结合本院药房药物价格与假体周围感染管理成本,比较两种方案的人均费用差异。

要点

  • 28天阿司匹林与Xa因子抑制剂人均药物费用分别为17.36美元与3,784.20美元。
  • 含随访费用时,28天疗程人均费用分别升至73,358.76美元与77,125.60美元。
  • 加权平均人均费用分别为237.38美元与4,370.93美元,Xa因子抑制剂最高高出1,980.6%。

核心结论

  • 由于原发性治疗费用、假体周围感染率差异及感染管理高成本,Xa因子抑制剂血栓预防的人均费用最高比阿司匹林方案高1,980.6%。
  • 在价值医疗时代,使用阿司匹林具有显著的费用优势。

研究设计与样本

  • 基于单一大型机构已发表的原发性全膝关节置换术后阿司匹林与Xa因子抑制剂血栓预防的假体周围感染率,结合本院药房药物价格与假体周围感染管理成本进行费用比较。
  • 假体周围感染成本包括二期感染翻修术费用,含或不含1年随访费用;并采用全国数据确定年度预计全膝关节置换术量。

主要发现

  • 28天疗程阿司匹林与Xa因子抑制剂人均药物费用分别为17.36美元与3,784.20美元。
  • 含随访费用时,28天疗程阿司匹林与Xa因子抑制剂人均费用分别增至73,358.76美元与77,125.60美元。
  • 28天疗程加权平均人均费用阿司匹林为237.38美元,Xa因子抑制剂为4,370.93美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin and oral factor Xa inhibitor thromboprophylaxis regimens are associated with similarly low rates of venous thromboembolism following total knee arthroplasty (TKA). However, the rate of prosthetic joint infection (PJI) is lower with aspirin use. This study aimed to compare the cost differential between aspirin and factor Xa inhibitor thromboprophylaxis with respect to PJI management. METHODS: We used previously published rates of PJI following aspirin and factor Xa inhibitor thromboprophylaxis in primary TKA patients at a single, large institution. Prices for individual drugs were obtained from our hospital's pharmacy service. The cost of PJI included that of 2-stage septic revision, with or without the cost of 1-year follow-up. National data were obtained to determine annual projected TKA volume. RESULTS: The per-patient costs associated with a 28-day course of aspirin versus factor Xa inhibitor thromboprophylaxis were $17.36 and $3,784.20, respectively. Including cost of follow-up, per-patient costs for a 28-day course of aspirin versus factor Xa inhibitors increased to $73,358.76 and $77,125.60, respectively. The weighted average per-patient costs for a 28-day course were $237.38 and $4,370.93, respectively. The annual cost difference could amount to over $14.1 billion in the United States by 2040. CONCLUSIONS: The per-patient cost associated with factor Xa inhibitor thromboprophylaxis is as much as 1,980.6% higher than that of an aspirin regimen due to increased costs of primary treatment, differential PJI rates, and high costs of management. In an era of value-based care, the use of aspirin is associated with major cost advantages.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Bergstein VE, Taylor WL, Weinblatt AI, et al. The Financial Burden of Aspirin versus Oral Factor Xa Inhibitors for Thromboprophylaxis Following Total Knee Arthroplasty. J Arthroplasty. 2023. PMID: 37858709. doi:10.1016/j.arth.2023.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。